JPMorgan raises AbbVie target price to $300 from $285
ABBV•JPMorgan raised its target price for AbbVie to $300 from $285.
Related News
Nuveen Municipal Credit Opportunities Fund rights offering set to issue 13.7 million shares
NMCO•
Gold edges higher after hitting a two-month low
GLD•
Samsung's AI riches lag Nvidia's money machine
SSNLF•
Japanese investors pulled money from foreign bonds for a second successive month in September
TLT•
Archrock, Inc.: JP Morgan cuts target price to $41 from $42
AROC•